Clinical trial
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed…
NCT00306293 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00306293 |
|---|---|
| Title | VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2 |
| Official title | The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Herpes Labialis |
| Intervention type | Drug |
| Interventions | valacyclovir |
| Enrollment | 70 |
| Start date | Feb 20, 2006 |
| Primary completion | Nov 27, 2006 |
| Completion | Nov 27, 2006 |
| First posted | Mar 23, 2006 |
| Last update posted | Mar 23, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: